• All sections
  • C - Chemistry; metallurgy
  • C07D - Heterocyclic compounds
  • C07D 233/61 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Patent holdings for IPC class C07D 233/61

Total number of patents in this class: 358

10-year publication summary

39
32
22
17
24
24
17
17
24
2
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

Principal owners for this class

Owner
All patents
This class
Probiodrug AG
76
7
University of Pittsburgh - Of the Commonwealth System of Higher Education
2912
7
Bristol-myers Squibb Company
5080
6
BIAL - Portela & CA, S.A.
243
6
PTC Therapeutics, Inc.
492
6
Merck Patent GmbH
5909
5
Centre National de La Recherche Scientifique
9632
5
Agency for Science, Technology and Research
3512
5
Institut Curie
531
5
Toyama Chemical Co., Ltd.
114
5
Seren Technologies Limited
9
5
Bayer Pharma AG
1096
4
President and Fellows of Harvard College
5792
4
Takeda Pharmaceutical Company Limited
2961
4
Dana-Farber Cancer Institute, Inc.
2455
4
Dicerna Pharmaceuticals, Inc.
278
4
EA Pharma Co., Ltd.
77
4
Taisho Pharmaceutical Co., Ltd.
844
4
Universite de Montpellier
920
4
Nissan Chemical Corporation
1725
4
Other owners 260